Liver Cirrhosis
📧 Sign up to get email alerts when something new happens for Liver Cirrhosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-05EMA Authorised: Iqirvo (Elafibranor) — Ipsen Pharma
Elafibranor (Iqirvo) by Ipsen Pharma has been authorised with conditional approval as an orphan medicine for liver cirrhosis and biliary dis…
-
EMA approval · 2026-04-09EMA Authorised: Kayshild (semaglutide) — Novo Nordisk A/S
EU medicines regulator authorised Kayshild (semaglutide) by Novo Nordisk A/S for non-alcoholic fatty liver disease and liver cirrhosis, with…
-
EMA approval · 2026-03-24EMA Authorised: Qaialdo (spironolactone) — Lipomed GmbH
Qaialdo is a spironolactone product by Lipomed GmbH that has been authorized in the EU. Indications include edema, heart failure, liver cirr…
-
EMA approval · 2026-02-20EMA Authorised: Lyvdelzi (previously Seladelpar Gilead) (seladelpar lysine dihydrate) — Gilead Sciences Ireland Unlimited Company
The EMA authorised Lyvdelzi (seladelpar lysine dihydrate) for liver cirrhosis with biliary involvement. The approval is conditional and desi…
-
FDA approval · 2026-02-05FDA Approved: BUMETANIDE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approves the original application for bumetanide (generic) from Novadoz Pharmaceuticals LLC, a loop diuretic indicated for edema associa…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-01-08FDA Approved: FUROSEMIDE — Original Application (Micro Labs Limited)
FDA approved the original application for furosemide from Micro Labs Limited.
-
FDA approval · 2026-01-07FDA Approved: METOLAZONE — Supplemental Application (Method Pharmaceuticals, LLC)
The FDA approved a supplemental application for METOLAZONE submitted by Method Pharmaceuticals, LLC.
-
FDA approval · 2025-09-12FDA Approved: ENBUMYST — Original Application (Corstasis USA LLC)
The FDA approves ENBUMYST (bumetanide) from Corstasis USA LLC via its Original Application (NDA219500).
-
FDA approval · 2025-09-08FDA Approved: FUROSEMIDE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for furosemide from Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc., updating/expandin…
-
EMA approval · 2025-07-28EMA Authorised: Iqirvo (Elafibranor) — Ipsen Pharma
The EMA authorised Iqirvo (elafibranor) for liver cirrhosis and biliary diseases with conditional approval, and it has orphan medicine desig…
-
FDA approval · 2025-07-17FDA Approved: FUROSEMIDE — Original Application (Aurobindo Pharma Limited)
FDA approves Aurobindo Pharma Limited's original ANDA for furosemide, a generic loop diuretic. The approval covers the generic product for i…
-
FDA approval · 2025-06-13FDA Approved: BUMETANIDE — Supplemental Application (Qilu Pharmaceutical Co., Ltd.)
FDA approved a supplemental application for bumetanide from Qilu Pharmaceutical Co., Ltd., authorizing the generic product's approval.
-
FDA approval · 2025-05-08FDA Approved: FUROSEMIDE — Supplemental Application (Eugia US LLC)
FDA approved a supplemental application for furosemide by Eugia US LLC under an ANDA, confirming approval of the supplement.
-
FDA approval · 2025-04-03FDA Approved: BUMETANIDE — Original Application (First Nation Group, LLC)
FDA approves bumetanide under an Original Application filed by First Nation Group, LLC (ANDA219291).
-
FDA approval · 2025-02-27FDA Approved: BUMETANIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for bumetanide, a loop diuretic used to treat edema due to congestive heart failur…
-
FDA approval · 2024-12-27FDA Approved: BUMETANIDE — Original Application (Advagen Pharma Limited)
FDA approved Advagen Pharma Limited's original ANDA for bumetanide, a loop diuretic used to treat edema associated with congestive heart fai…
-
FDA approval · 2024-12-13FDA Approved: FUROSEMIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' original application for furosemide, enabling a generic version of the loop diuretic to be marketed.
-
FDA approval · 2024-10-01FDA Approved: FUROSEMIDE — Supplemental Application (Phlow Corporation)
The FDA approved a supplemental application for furosemide from Phlow Corporation, authorizing an additional or revised approval for the diu…
-
FDA approval · 2023-06-28FDA Approved: SPIRONOLACTONE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for Spironolactone from Amneal Pharmaceuticals LLC.
-
FDA approval · 2023-06-23FDA Approved: SPIRONOLACTONE — Supplemental Application (Oxford Pharmaceuticals, LLC)
FDA approved a supplemental application for spironolactone by Oxford Pharmaceuticals, LLC. The approval allows continued marketing of the ge…
-
FDA approval · 2023-05-17FDA Approved: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Sun Pharmaceutical's spironolactone and hydrochlorothiazide combination product. The submission …
-
FDA approval · 2023-05-10FDA Approved: FUROSEMIDE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for furosemide submitted by Hikma Pharmaceuticals USA Inc.
-
FDA approval · 2023-02-17FDA Approved: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for the generic Spironolactone and Hydrochlorothiazide from Mylan Pharmaceuticals Inc., a combinatio…
-
FDA approval · 2022-12-16FDA Approved: FUROSEMIDE — Original Application (Lifestar Pharma LLC)
FDA approved Lifestar Pharma LLC's original application for furosemide, authorizing the generic version of the diuretic for its labeled indi…
-
FDA approval · 2022-10-24FDA Approved: METOLAZONE — Original Application (Ingenus Pharmaceuticals LLC)
FDA approves Metolazone via Original Application for a generic version by Ingenus Pharmaceuticals LLC. The approval supports its use for ede…